Global Acute Migraine Drugs Market - 2021-2028
全球急性偏頭痛治療藥市場主要促進因素，是世界各國的偏頭痛患者增加，及CGRP (抑鈣素基因系肽) 拮抗劑的上市等。另一方面，副作用的問題也有可能妨礙市場進一步成長。
The global acute migraine drugs market size was valued US$ XX million in 2020 and is estimated to reach US$ XX million by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).
Migraine is a neurological disorder that includes headaches, nausea, inability to smell, increased sensitivity to sound and light, and numbness. These headaches occur on one side of the head with different durations and intensities. Acute Migraine Drugs are given to terminate the migraine attacks.
A migraine is a headache that causes severe throbbing pain, normally on one side of the head. Its often accompanied by nausea, vomiting, and severe sensitivity to light and sound, and migraine attacks can last for hours to days. The pain can be so sharp that it interferes with your daily activities. Moreover, it affects children, teenagers, and adults and can grow through four stages: prodrome, aura, attack, and post-drome. According to the article (Research gate), not everyone who has migraines goes through all stages (Research gate), published on April 8, 2021. The prevalence of migraines was 18.2% among females and 6.5% among males-approximately 23% of households contained at least one member suffering from migraines. Migraine prevalence is higher in whites than in blacks and was inversely related to household income. Thus, a rise in the prevalence of migraine cases leads to increased demand for migraine treatment drugs.
Allergan is under license to Merck & Co. has developed Ubrogepant (Ubrelvy), an orally administered, small molecule, highly-selective, calcitonin gene-related peptide (CGRP) antagonist that received its first global approval in the USA for the acute treatment of migraine (± aura) in adults on December 2019. Also, the recommended dosage of oral ubrogepant is 50 mg or 100 mg taken as needed without regard to food. Hence, with increasing launch of new drugs for the treatment of migraine is expected to drive the growth of market over the forecast period.
In October 2019, the U.S. Food and Drug Administration (FDA) approved the first-in-class "ditan"-lasmiditan 50 mg and 100 mg tablets. For acute treatment of migraine with or without aura in adults. Lasmiditan is a 5-HT agonist with an over 440 times more potent binding affinity for 5-HT1F than 5-HT1B and 5-HT1D receptors and which potently inhibits markers of electrical stimulation of the trigeminal ganglion. In addition, 50-200 mg of the dose is recommended depending on the pain intensity. It is not recommended to take more than one dose in a day or drive vehicles up to 8 h after taking the drug; if taken, then it leads to most common side effects, including dizziness, fatigue, paresthesia, and sedation. Therefore, besides its benefits for treating acute migraines, few side effects are expected to hamper the market growth.
The coronavirus disease 2019 (COVID-19) pandemic has caused overwhelming challenges in healthcare worldwide. Migraine is one of the commonest and extremely disabling chronic neurological diseases in the world. During the pandemic and lockdown, migraine patients face a huge problem getting utmost care because of difficulty in admittance, forced social isolation, and encountering a health system that is getting overwhelmed. Moreover, in the absence of therapeutic procedures, other preventive therapies such as self-injectable monoclonal antibodies, neuromodulation devices and oral corticosteroids are used. The patients must be protected by reducing their visits to the clinics and emergency departments.
Moreover, paradoxically multiple triggers are in operation, which is likely to increase their headache frequency. Hence, physicians should be aware of the game's new rules in handling migraines during the pandemic so that these patients get maximum treatment and care and don't feel left out. The pandemic is interrupting the medical supply chain, and many companies will vary to other geographic regions in the future to ensure that products remain available and protect their supply chain. Thus, the market will undergo impetus during the forecast period.
The triptans segment accounted for the largest market share in 2020. It is an effective first-line treatment for moderate to severe migraine, and several triptans are available with different pharmacokinetics and routes of administration. As 5-hydroxytryptamine receptor agonists, they are pharmacologically specific for migraines and can be used in adequate doses with few major adverse effects.
Moreover, for migraines with aura, evidence suggests that the best results are achieved by taking the triptan at the onset of pain rather than the onset of aura. However, taking a triptan during a typical aura seems to be safe. Accordingly, a meta-analysis of the effectiveness of the seven available triptans (almotriptan [Axert], eletriptan [Relpax], frovatriptan [Frova], naratriptan [Amerge], rizatriptan [Maxalt], sumatriptan [Imitrex], and zolmitriptan [Zomig]) found that standard doses provided headache relief at two hours in 42% to 76% of patients and complete pain relief at two hours in 18% to 50%. In addition, for headache relief at two hours, standard-dose triptans alone performed better than ergot alkaloids, equal to or better than NSAIDs and acetaminophen, and equal to or slightly worse than combination therapies (triptan plus NSAID or acetaminophen). For example, sumatriptan is the most extensively studied triptan. Its effectiveness varies by dose and route of administration. All triptans have strong evidence of effectiveness, but few head-to-head comparisons have been performed. The strongest evidence and most favorable outcomes are reported for subcutaneous sumatriptan, rizatriptan orally disintegrating tablets (Maxalt Mlt), zolmitriptan orally disintegrating tablets (Zomig Zmt), and eletriptan tablets. Therefore, sumatriptan as a subcutaneous 6-mg injection has the most favorable NNT for complete pain relief at two hours.
North America accounted for the largest revenue share in 2020. The growth of this region is attributed to the high prevalence of acute migraine, increased usage of CGRP based therapies, increasing adoption of novel therapeutics, and large target populations in the U.S. are the factors expected to boost the market in the forecast period. For instance, according to the Journal of Pain Research, published on 20 April 2021, a migraine with brainstem aura (MBA) accompanied by disorders of consciousness (DOC) is a rare subtype of migraine. The pathophysiology of MBA with DOC has not been elucidated yet. Some patients have a family history of migraines, and women are more affected than men. The aura symptoms are diverse; however, the clinical manifestations are more complicated when MBA is combined with DOC. The first-generation CGRP receptor antagonists, gepants, were effective for the abortive treatment of migraines. However, they were not fully developed because of hepatotoxicity. Ubrogepant, also known as MK-1602, is an oral, small-molecule CGRP receptor antagonist for acute migraine treatment. A study found that 2 hours after ubrogepant administration, the patient's headache and aura symptoms were relieved. Unlike other gepants, ubrogepant has no hepatotoxicity at therapeutic doses.
In addition, the ACHIEVE II Randomized Clinical Trial study found that both 50-mg and 25-mg doses can significantly relieve migraines. However, only a 50 mg dose helped to reduce the aura. A Phase III, randomized, 52-week extension trial further confirmed the safety of long-term intermittent use of ubrogepant 50 and 100 mg doses. Short-term use of ubrogepant is not related to an increased risk for adverse events. The time course of ubrogepant efficacy was demonstrated to 48 h, providing evidence of the long-lasting effect. Therefore for the subjective feelings of patients, the potential benefits of ubrogepant could improve patient-centered satisfaction. Thus, the North American region holds the largest market share in the forecast period from the above statements.
The acute migraine drugs market is highly competitive with presence of several global companies. Some of the key players which are contributing to the growth of the market include GSK, Teva, Pfizer, Novartis, Sun Pharma, Merck and Johnson and Johnson. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the acute migraine drugs market globally.
Sun Pharmaceutical Industries Limited is an Indian multinational pharmaceutical company. It manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) primarily in India and the United States. Moreover, the company offers formulations in various therapeutic areas, such as cardiology, psychiatry, neurology, gastroenterology and diabetology. It provides APIs such as warfarin, carbamazepine, etodolac, clorazepate, anti-cancers, steroids, peptides, sex hormones, and controlled substances. Additionally, the company has a global presence in over 150 countries across branded and generic segments. It is backed by strong R&D capabilities across dosage forms like injectables, sprays, ointments, creams, liquids, tablets and capsules.
Sun Pharmaceutical Industries Limited is into continuous manufacturing of acute migraine drugs including Sumatriptan Succinate Tablets (sue-muh-TRIP-tan SUX-in-ate) and Sumatriptan Injection, USP (sue-muh-TRIP-tan).
The global acute migraine drugs market report would provide an access to an approx. 46 market data table, 47 figures and 180 pages.